IRAQ

CERVICAL CANCER PROFILE

Morbidity and Mortality

Crude cervical cancer incidence per 100 000 women (2020): 1.4
Age-standardized cervical cancer incidence per 100 000 women (2020): 2.2
Cumulative risk of cervical cancer, ages 0-74 (2020): 0.3%
Cervical cancer deaths (2019): 160
Cervical cancer mortality-to-incidence ratio (2020): 0.67
Population-based cancer registry exists (2021): Yes

Primary Prevention

HPV vaccination programme coverage among girls (2020)

HPV vaccination programme (2020):
HPV included in national vaccination programme: No
Scale of vaccination programme:
Year of introduction:
Primary target cohort:

Related risk factors:
Tobacco use prevalence, women aged 15+ years (2020): 2%
Condom use at last high-risk sex (-):
HIV incidence per 1000, women aged 15+ years (2020): ND

Secondary Prevention

National screening programme for cervical cancer exists (2021):
Primary screening test used (2021):
Target age range of programme (2021):
Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021):
Clearly defined referral system exists from primary care to secondary and tertiary care (2021):

Treatment and Supportive Care

National guidelines on cervical cancer management exist (2021):

Cancer diagnosis and treatment services generally available (2021):
Cancer centre or cancer department at tertiary level:
Pathology services (laboratories):
Cancer surgery:
Chemotherapy:
Radiotherapy:

Palliative care for patients with NCDs in the public health system generally available (2021):
In primary health care facilities:
In community or home-based care:

WHO Cervical Cancer Elimination Strategy Targets for 2030

90% of girls fully vaccinated with the HPV vaccine by the age of 15
70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
90% of women identified with cervical disease receive treatment

World Health Organization - Cervical Cancer Country Profiles, 2021